Shares of Safeguard Scientifics, Inc (NYSE:SFE) have earned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.
Brokers have set a twelve-month consensus price target of $17.00 for the company and are expecting that the company will post $1.53 EPS for the current quarter, according to Zacks. Zacks has also given Safeguard Scientifics an industry rank of 163 out of 256 based on the ratings given to its competitors.
A number of equities analysts have recently issued reports on the company. ValuEngine cut Safeguard Scientifics from a “sell” rating to a “strong sell” rating in a report on Thursday, June 27th. Zacks Investment Research raised Safeguard Scientifics from a “hold” rating to a “strong-buy” rating and set a $13.00 price target for the company in a report on Tuesday, May 7th.
Safeguard Scientifics (NYSE:SFE) last released its quarterly earnings results on Thursday, May 2nd. The asset manager reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.25. As a group, sell-side analysts anticipate that Safeguard Scientifics will post 1.37 earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the stock. Yakira Capital Management Inc. increased its stake in shares of Safeguard Scientifics by 2.7% in the 1st quarter. Yakira Capital Management Inc. now owns 818,289 shares of the asset manager’s stock valued at $8,878,000 after buying an additional 21,600 shares during the period. Legal & General Group Plc increased its stake in shares of Safeguard Scientifics by 5.2% in the 4th quarter. Legal & General Group Plc now owns 92,286 shares of the asset manager’s stock valued at $796,000 after buying an additional 4,603 shares during the period. Geode Capital Management LLC increased its stake in shares of Safeguard Scientifics by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 191,298 shares of the asset manager’s stock valued at $1,648,000 after buying an additional 9,318 shares during the period. Zeke Capital Advisors LLC acquired a new stake in shares of Safeguard Scientifics in the 1st quarter valued at $2,212,000. Finally, Almitas Capital LLC increased its stake in shares of Safeguard Scientifics by 63.5% in the 1st quarter. Almitas Capital LLC now owns 402,998 shares of the asset manager’s stock valued at $4,373,000 after buying an additional 156,580 shares during the period. 68.28% of the stock is owned by hedge funds and other institutional investors.
About Safeguard Scientifics
Safeguard Scientifics, Inc no longer investing. It is a private equity and venture capital firm specializing in expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, growth stage, and early stage financings. It initially invests in a Series A-C round and opportunistically in a seed round.
Featured Article: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Safeguard Scientifics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safeguard Scientifics and related companies with MarketBeat.com's FREE daily email newsletter.